BNTX – BioNTech SE
Float Short %
2.52
Margin Of Safety %
Put/Call OI Ratio
0.85
EPS Next Q Diff
-1.89
EPS Last/This Y
-0.04
EPS This/Next Y
0.79
Price
96.25
Target Price
141.85
Analyst Recom
1.55
Performance Q
-6.24
Relative Volume
1.23
Beta
1.39
Ticker: BNTX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-11-10 | BNTX | 105.04 | 0.84 | 0.28 | 44201 |
| 2025-11-11 | BNTX | 108.72 | 0.83 | 0.20 | 44466 |
| 2025-11-12 | BNTX | 111.61 | 0.77 | 1.13 | 47228 |
| 2025-11-13 | BNTX | 103.88 | 0.78 | 0.53 | 48161 |
| 2025-11-14 | BNTX | 103.03 | 0.77 | 1.40 | 49250 |
| 2025-11-17 | BNTX | 102.75 | 0.78 | 3.11 | 49564 |
| 2025-11-18 | BNTX | 102.5 | 0.81 | 1.74 | 50387 |
| 2025-11-19 | BNTX | 101.35 | 0.82 | 2.09 | 50778 |
| 2025-11-20 | BNTX | 96.9 | 0.83 | 2.19 | 51065 |
| 2025-11-21 | BNTX | 95.65 | 0.80 | 1.43 | 50871 |
| 2025-11-24 | BNTX | 96.54 | 0.93 | 0.32 | 42830 |
| 2025-11-25 | BNTX | 99.65 | 0.90 | 0.90 | 43763 |
| 2025-11-26 | BNTX | 102.18 | 0.90 | 0.13 | 44156 |
| 2025-12-01 | BNTX | 97.38 | 0.88 | 1.00 | 43024 |
| 2025-12-02 | BNTX | 96.04 | 0.89 | 1.07 | 43164 |
| 2025-12-03 | BNTX | 96.73 | 0.87 | 0.11 | 43247 |
| 2025-12-04 | BNTX | 95.52 | 0.85 | 1.16 | 43927 |
| 2025-12-05 | BNTX | 96.24 | 0.85 | 0.37 | 44426 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-11-10 | BNTX | 105.07 | -84.8 | -787.1 | -3.24 |
| 2025-11-11 | BNTX | 108.65 | -107.0 | -837.6 | -4.23 |
| 2025-11-12 | BNTX | 111.64 | -107.0 | -810.7 | -4.23 |
| 2025-11-13 | BNTX | 103.82 | -113.5 | -536.4 | -4.13 |
| 2025-11-14 | BNTX | 103.06 | -113.5 | -710.4 | -4.13 |
| 2025-11-17 | BNTX | 102.74 | -113.5 | -909.4 | -4.02 |
| 2025-11-18 | BNTX | 102.52 | -113.5 | -916.1 | -4.02 |
| 2025-11-19 | BNTX | 101.43 | -113.5 | -883.1 | -4.02 |
| 2025-11-20 | BNTX | 96.96 | -105.5 | -761.0 | -3.87 |
| 2025-11-21 | BNTX | 95.50 | -105.5 | -849.8 | -3.80 |
| 2025-11-24 | BNTX | 96.54 | -105.5 | -948.8 | -3.80 |
| 2025-11-25 | BNTX | 99.71 | -105.5 | -1032.2 | -3.80 |
| 2025-11-26 | BNTX | 102.73 | -105.5 | -1017.3 | -3.80 |
| 2025-12-01 | BNTX | 97.45 | -105.5 | -732.3 | -3.82 |
| 2025-12-02 | BNTX | 96.11 | -105.5 | -875.2 | -3.82 |
| 2025-12-03 | BNTX | 96.73 | -105.5 | -953.1 | -3.82 |
| 2025-12-04 | BNTX | 96.00 | -105.5 | -903.0 | -3.82 |
| 2025-12-05 | BNTX | 96.25 | -105.5 | -939.7 | -3.27 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-11-10 | BNTX | 0.00 | 0.77 | 2.61 |
| 2025-11-11 | BNTX | 0.00 | 0.77 | 2.61 |
| 2025-11-12 | BNTX | 0.00 | 0.77 | 2.57 |
| 2025-11-13 | BNTX | 0.00 | 0.77 | 2.57 |
| 2025-11-14 | BNTX | 0.00 | 0.77 | 2.57 |
| 2025-11-17 | BNTX | 0.00 | 1.58 | 2.55 |
| 2025-11-18 | BNTX | 0.00 | 1.58 | 2.55 |
| 2025-11-19 | BNTX | 0.00 | 1.58 | 2.55 |
| 2025-11-20 | BNTX | 0.00 | 1.58 | 2.55 |
| 2025-11-21 | BNTX | 0.00 | 1.58 | 2.55 |
| 2025-11-24 | BNTX | 0.00 | -2.43 | 2.55 |
| 2025-11-25 | BNTX | 0.00 | -2.43 | 2.55 |
| 2025-11-26 | BNTX | 0.00 | -2.43 | 2.52 |
| 2025-12-01 | BNTX | 0.00 | -2.43 | 2.52 |
| 2025-12-02 | BNTX | 0.00 | -2.43 | 2.52 |
| 2025-12-03 | BNTX | 0.00 | -2.43 | 2.52 |
| 2025-12-04 | BNTX | 0.00 | -2.43 | 2.52 |
| 2025-12-05 | BNTX | 0.00 | -2.43 | 2.52 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.14
Avg. EPS Est. Current Quarter
-0.06
Avg. EPS Est. Next Quarter
-2.03
Insider Transactions
Institutional Transactions
-2.43
Beta
1.39
Average Sales Estimate Current Quarter
823
Average Sales Estimate Next Quarter
219
Fair Value
Quality Score
56
Growth Score
33
Sentiment Score
2
Actual DrawDown %
79.3
Max Drawdown 5-Year %
-82.2
Target Price
141.85
P/E
Forward P/E
PEG
P/S
6.55
P/B
1.07
P/Free Cash Flow
EPS
-2.63
Average EPS Est. Cur. Y
-3.27
EPS Next Y. (Est.)
-2.47
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-17.92
Relative Volume
1.23
Return on Equity vs Sector %
-30
Return on Equity vs Industry %
-15.1
EPS 1 7Days Diff
0.6
EPS 1 30Days Diff
1
EBIT Estimation
-939.7
BioNTech SESector: Healthcare
Industry: Biotechnology
Employees: 6772
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
stock quote shares BNTX – BioNTech SE Stock Price stock today
news today BNTX – BioNTech SE stock forecast ,stock prediction 2023 2024 2025
marketwatch BNTX – BioNTech SE yahoo finance google finance
stock history BNTX – BioNTech SE invest stock market
stock prices BNTX premarket after hours
ticker BNTX fair value insiders trading